{"id":480136,"date":"2020-04-20T09:16:01","date_gmt":"2020-04-20T09:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=480136"},"modified":"2020-04-20T09:16:01","modified_gmt":"2020-04-20T09:16:01","slug":"prostate-cancer-diagnostics-market-size-is-expected-to-reach-usd-765-billion-by-2027-grand-view-research-inc","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/prostate-cancer-diagnostics-market-size-is-expected-to-reach-usd-765-billion-by-2027-grand-view-research-inc_480136.html","title":{"rendered":"Prostate Cancer Diagnostics Market Size Is Expected To Reach USD 7.65 Billion By 2027 : Grand View Research Inc."},"content":{"rendered":"
\"Prostate<\/a><\/p>\n
\n
Grand View Research, Inc. – Market Research And Consulting.<\/div>\n<\/div>\n<\/div>\n
According to report published by Grand View Research, The global prostate cancer diagnostics market size was valued at USD 2.83 billion in 2019 and is anticipated to expand at a CAGR of 13.2% during the forecast period. Increasing prevalence of prostate cancer is one of the major factors propelling the demand for diagnostic products. <\/div>\n

The global prostate cancer diagnostics market<\/a><\/strong> size is expected to reach USD 7.65 billion by 2027, registering a CAGR of 13.2% during the forecast period, according to a new report by Grand View Research, Inc. Major drivers include increasing government initiatives, high prevalence of prostate cancer, and technological advancements in confirmatory diagnostic tests.<\/p>\n

High prevalence of the disease across the world is anticipated to be one of the major factors propelling the growth. According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer during the lifetime. It also states that the disease is the second most common form of cancer in U.S. after skin melanoma with over 174,650 new cases diagnosed in 2019.<\/p>\n

Rise in government initiatives to enhance research associated with effective diagnosis and treatment is expected to boost growth of the market during the forecast period. For instance, the National Cancer Institute (NCI) initiated the study Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress (RESPOND). It is the largest collaboration to study the non-biological and biological factors associated with the disease among African American men. The initiative was launched by the NCI, National Institute on Minority Health, and Health Disparities in collaboration with Prostate Cancer Foundation; with a funding of USD 26 million.<\/p>\n

Researchers from the University of Norfolk and East Anglia have developed a non-invasive urine test-the PUR test-for the diagnosis of aggressive prostate cancer. This test is performed on samples collected at home thereby preventing uncomfortable rectal examination. Additionally, researchers at Karolinska and KTH Institute concluded that the use of Artificial Intelligence (AI) in spatial transcriptomics can aid in the early detection, thereby, improving clinical diagnosis and treatment. Thus, such advancements are anticipated to positively impact the market growth in near future.<\/p>\n

Approval of new diagnostic tests are expected to further boost market growth. For instance, in 2019, Bio Techne announced the approval from the New York State Department of Health for a liquid biopsy based test named ExoDx Prostate IntelliScore. The test assists clinicians to determine the need for biopsy with ambiguous PSA test result. Thus, rising disease prevalence coupled with technological advancements are the factors anticipated to fuel the market growth during the forecast period.<\/p>\n

\"U.S.<\/p>\n

Request a sample Copy of the <\/span>Prostate Cancer Diagnostics Market Research Report @ <\/span><\/strong>https:\/\/www.grandviewresearch.com\/industry-analysis\/prostate-cancer-diagnostics-market\/request\/rs1<\/a><\/strong><\/p>\n

Key Takeaways Of The Report :<\/strong><\/p>\n